Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade

IF 1.5 4区 医学 Q4 ONCOLOGY Cancer Radiotherapie Pub Date : 2024-08-01 DOI:10.1016/j.canrad.2024.01.004
{"title":"Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade","authors":"","doi":"10.1016/j.canrad.2024.01.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to develop nomograms that combine clinical factors and MRI tumour regression grade to predict the pathological response of mid-low locally advanced rectal cancer to neoadjuvant chemoradiotherapy.</p></div><div><h3>Methods</h3><p>The retrospective study included 204 patients who underwent neoadjuvant chemoradiotherapy and surgery between January 2013 and December 2021. Based on pathological tumour regression grade, patients were categorized into four groups: complete pathological response (pCR, <em>n</em> <!-->=<!--> <!-->45), non-complete pathological response (non-pCR; <em>n</em> <!-->=<!--> <!-->159), good pathological response (pGR, <em>n</em> <!-->=<!--> <!-->119), and non-good pathological response (non-pGR, <em>n</em> <!-->=<!--> <!-->85). The patients were divided into a training set and a validation set in a 7:3 ratio. Based on the results of univariate and multivariate analyses in the training set, two nomograms were respectively constructed to predict complete and good pathological responses. Subsequently, these predictive models underwent validation in the independent validation set. The prognostic performances of the models were evaluated using the area under the curve (AUC).</p></div><div><h3>Results</h3><p>The nomogram predicting complete pathological response incorporates tumour length, post-treatment mesorectal fascia involvement, white blood cell count, and MRI tumour regression grade. It yielded an AUC of 0.787 in the training set and 0.716 in the validation set, surpassing the performance of the model relying solely on MRI tumour regression grade (AUCs of 0.649 and 0.530, respectively). Similarly, the nomogram predicting good pathological response includes the distance of the tumour's lower border from the anal verge, post-treatment mesorectal fascia involvement, platelet/lymphocyte ratio, and MRI tumour regression grade. It achieved an AUC of 0.754 in the training set and 0.719 in the validation set, outperforming the model using MRI tumour regression grade alone (AUCs of 0.629 and 0.638, respectively).</p></div><div><h3>Conclusions</h3><p>Nomograms combining MRI tumour regression grade with clinical factors may be useful for predicting pathological response of mid-low locally advanced rectal cancer to neoadjuvant chemoradiotherapy. The proposed models could be applied in clinical practice after validation in large samples.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Radiotherapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S127832182400088X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

This study aimed to develop nomograms that combine clinical factors and MRI tumour regression grade to predict the pathological response of mid-low locally advanced rectal cancer to neoadjuvant chemoradiotherapy.

Methods

The retrospective study included 204 patients who underwent neoadjuvant chemoradiotherapy and surgery between January 2013 and December 2021. Based on pathological tumour regression grade, patients were categorized into four groups: complete pathological response (pCR, n = 45), non-complete pathological response (non-pCR; n = 159), good pathological response (pGR, n = 119), and non-good pathological response (non-pGR, n = 85). The patients were divided into a training set and a validation set in a 7:3 ratio. Based on the results of univariate and multivariate analyses in the training set, two nomograms were respectively constructed to predict complete and good pathological responses. Subsequently, these predictive models underwent validation in the independent validation set. The prognostic performances of the models were evaluated using the area under the curve (AUC).

Results

The nomogram predicting complete pathological response incorporates tumour length, post-treatment mesorectal fascia involvement, white blood cell count, and MRI tumour regression grade. It yielded an AUC of 0.787 in the training set and 0.716 in the validation set, surpassing the performance of the model relying solely on MRI tumour regression grade (AUCs of 0.649 and 0.530, respectively). Similarly, the nomogram predicting good pathological response includes the distance of the tumour's lower border from the anal verge, post-treatment mesorectal fascia involvement, platelet/lymphocyte ratio, and MRI tumour regression grade. It achieved an AUC of 0.754 in the training set and 0.719 in the validation set, outperforming the model using MRI tumour regression grade alone (AUCs of 0.629 and 0.638, respectively).

Conclusions

Nomograms combining MRI tumour regression grade with clinical factors may be useful for predicting pathological response of mid-low locally advanced rectal cancer to neoadjuvant chemoradiotherapy. The proposed models could be applied in clinical practice after validation in large samples.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用基于磁共振成像肿瘤回归分级的提名图预测直肠癌新辅助化疗的反应。
目的:本研究旨在开发结合临床因素和磁共振成像肿瘤回归分级的提名图,以预测中低位局部晚期直肠癌对新辅助化放疗的病理反应:该回顾性研究纳入了2013年1月至2021年12月期间接受新辅助化放疗和手术的204例患者。根据病理肿瘤消退等级,将患者分为四组:完全病理反应(pCR,45人)、非完全病理反应(非CR;159人)、良好病理反应(pGR,119人)和非良好病理反应(非GR,85人)。患者按 7:3 的比例分为训练集和验证集。根据训练集的单变量和多变量分析结果,分别构建了两个预测完全和良好病理反应的提名图。随后,这些预测模型在独立验证集中进行了验证。使用曲线下面积(AUC)对模型的预后性能进行评估:预测完全病理反应的提名图包含肿瘤长度、治疗后直肠间筋膜受累情况、白细胞计数和磁共振成像肿瘤回归分级。在训练集和验证集上的AUC分别为0.787和0.716,超过了仅依靠MRI肿瘤回归分级的模型(AUC分别为0.649和0.530)。同样,预测良好病理反应的提名图包括肿瘤下缘与肛缘的距离、治疗后直肠间筋膜受累情况、血小板/淋巴细胞比率和 MRI 肿瘤回归分级。该模型在训练集中的AUC为0.754,在验证集中的AUC为0.719,优于单独使用MRI肿瘤回归分级的模型(AUC分别为0.629和0.638):结合磁共振成像肿瘤回归分级和临床因素的提名图可能有助于预测中低位局部晚期直肠癌对新辅助化放疗的病理反应。所提出的模型经大样本验证后可应用于临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Radiotherapie
Cancer Radiotherapie 医学-核医学
CiteScore
2.20
自引率
23.10%
发文量
129
审稿时长
63 days
期刊介绍: Cancer/radiothérapie se veut d''abord et avant tout un organe francophone de publication des travaux de recherche en radiothérapie. La revue a pour objectif de diffuser les informations majeures sur les travaux de recherche en cancérologie et tout ce qui touche de près ou de loin au traitement du cancer par les radiations : technologie, radiophysique, radiobiologie et radiothérapie clinique.
期刊最新文献
Editorial Board Étude prospective longitudinale sur l’évolution de la mémoire autobiographique de patients irradiés pour une tumeur bénigne de la base du crâne Multicriteria optimization of radiation therapy: Towards empowerment and standardization of reverse planning for head and neck squamous cell carcinoma Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade ‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1